(12) **Translation of European patent specification**

(11) **NO/EP 3043181 B1**

(19) NO

NORWAY

(51) Int Cl.
G01N 33/574 (2006.01)
A61K 39/00 (2006.01)
C07K 16/28 (2006.01)
C07K 16/30 (2006.01)
C12N 5/00 (2006.01)
C12N 5/09 (2010.01)
C12Q 1/68 (2018.01)
G01N 33/50 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.06.22
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.04.08
(86)	European Application Nr.	15198767.4
(86)	European Filing Date	2009.01.13
(87)	The European Application's Publication Date	2016.07.13
(30)	Priority	2008.01.15, US, 11324 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(73)	Proprietor	The Board of Trustees of the Leland Stanford Junior University, Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038, USA
(72)	Inventor	WEISSMAN, Irving, L., 4147 Jefferson Avenue, Redwood City, CA 94061, USA MAJETI, Ravindra, Stanford Institute for Stem Cell Bio andRegenerative Medicine1050 Arastradero Road Building A, Stanford, CA 94304, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Hoffsveien 1A, 0275 OSLO, Norge

(54) Title **MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS**

(56) References Cited:

US-A1- 2007 287 163
US-B2- 6 733 743
US-B1- 6 491 917
EP-A1- 2 111 869
US-A1- 2004 213 792
RAVINDRA MAJETI ET AL: "CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells", CELL, vol. 138, no. 2, 1 July 2009 (2009-07-01), pages 286-299, XP055277135, US ISSN: 0092-8674, DOI: 10.1016/j.cell.2009.05.045

YOSHIKANE KIKUSHIGE ET AL: "TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells", CELL STEM CELL, CELL PRESS, US, vol. 7, no. 6, 6 October 2010 (2010-10-06) , pages 708-717, XP028184581, ISSN: 1934-5909, DOI: 10.1016/J.STEM.2010.11.014 [retrieved on 2010-11-17]
JOSÉ IGNACIO MARTIN-SUBERO ET AL: "Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia", CANCER GENETICS AND CYTOGENETICS., vol. 127, no. 2, 1 June 2001 (2001-06-01), pages 174-176, XP055405588, US ISSN: 0165-4608, DOI: 10.1016/S0165-4608(00)00431-3
HOSEN N ET AL: "CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia", PNAS,, vol. 104, no. 26, 26 June 2007 (2007-06-26), pages 11008-11013, XP008109009, DOI: 10.1073/PNAS.0704271104
M. JAN ET AL: "Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 12, 7 March 2011 (2011-03-07), pages 5009-5014, XP055029836, ISSN: 0027-8424, DOI: 10.1073/pnas.1100551108
JAISWAL SIDDHARTHA ET AL: "CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis", CELL, CELL PRESS, US, vol. 138, no. 2, 1 July 2009 (2009-07-01), pages 271-285, XP009160236, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2009.05.046
CLARKE MICHAEL F ET AL: "Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells", CANCER RESEARCH, AACR, US PHILADELPHIA, PA, vol. 66, no. 19, 1 October 2006 (2006-10-01), pages 9339-9344, XP002580692, ISSN: 1538-7445
JAMIESON C ET AL: "Increased expression of CD47 is a constant marker in mouse and human myeloid leukemias", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 106, 1 January 2005 (2005-01-01), page 911A, XP008138745, ISSN: 0006-4971

Krav

1. Monoklonalt antistoff rettet mot humant CD47 som blokkerer interaksjonen mellom humant CD47 og SIRPα, for anvendelse i behandling av human akutt myeloid leukemi (AML) ved å stimulere fagocytose av AML leukemiske stamceller (LSC) av makrofager,
hvor antistoffet rettet mot humant CD47 blir anvendt i kombinasjon med ett eller flere ytterligere monoklonale antistoffer rettet mot en eller flere av de følgende markører: CD96, CD97, CD99, CD180, PTHR2, HAVCR2, CD123, CD44 og CD33.

2. Monoklonalt antistoff rettet mot humant CD47 for anvendelse ifølge krav 1, hvor de monoklonale antistoffene er humane eller humaniserte antistoffer.